Smart scans and DNA tests could tailor lymphoma therapy, reducing chemo for some

NCT ID NCT06050694

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new way to treat diffuse large B-cell lymphoma (DLBCL) by using PET scans and blood DNA tests early in treatment to decide the best next steps. About 40 adults with untreated DLBCL will start standard chemo, then get either shorter chemo if tests show low risk, or a new drug (glofitamab) if high risk. The goal is to see if this personalized approach is feasible and safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Jewish General Hospital

    RECRUITING

    Montreal, Quebec, H3T 1E2, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Princess Margaret Cancer Centre

    NOT_YET_RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

  • Princess Margaret Cancer Centre

    RECRUITING

    Toronto, Ontario, M5G 2M9, Canada

    Contact Phone: •••-•••-•••• Email: •••••@•••••